| Abstrakt: |
A study conducted at Zhengzhou University in China explored the role of Fructosamine-3-kinase (FN3K) in breast cancer cells. The researchers used homology modeling, virtual screening, molecular docking, molecular dynamics simulations, and cytotoxicity assays to examine the efficacy of various anticancer molecules in modulating FN3K activity and Nrf2-mediated antioxidant signaling. The study found that certain anticancer drugs, including gefitinib, sorafenib, neratinib, tamoxifen citrate, and cyclosporine A, enhanced FN3K expression and altered antioxidant signaling in breast cancer cells. Oxaliplatin, on the other hand, downregulated FN3K expression and modulated antioxidant signaling. The study suggests that existing anticancer drugs may have implications for modulating FN3K activity in breast cancer. [Extracted from the article] |
